Distribution and amount of pigment within the ciliary body and iris of dogs with blue and brown irides

Newkirk, Kim M.; Haines, D. K.; Calvarese, Sara T.; Esson, Doug W.; Chandler, Heather L.

doi:10.1111/j.1463-5224.2009.00756.x

Cited by 5 publications

(6 citation statements)

References 13 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite apparent similar pigmentation of the ciliary processes in dogs with blue irises: as in the Siberian Husky breed, IOP control was only observed in 2/5 blue‐eyed Siberian Huskies treated with MPTSCP. One patient was still normotensive on minimal medications 14 months postoperatively, and another patient was well controlled for 12 months after MP‐TSCP before elevated IOPs occurred.…”

Section: Discussionmentioning

confidence: 91%

“…The treated breeds included the Siberian Husky (n = 5), Golden Retriever (n = 3), Shih Tzu (n = 3), Jack Russell terrier (n = 2), Cocker Spaniel (n = 2), mixed breed dog (n = 4), and 1 dog each of the [14][15][16][17][18][19][20]. At the 6-month recheck, mean IOP was available for 14 eyes and was 19 ± 12 mm Hg (range: 10-51 mm Hg; median: 16; quartiles: [11][12][13][14][15][16][17][18][19]. At the longterm recheck (9 to12-month), mean IOP was available for 8 eyes and was 21 ± 7 mm Hg (range: 14-32 mm Hg; median: 19; quartiles: 16-29).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Preliminary findings in 30 dogs treated with micropulse transscleral cyclophotocoagulation for refractory glaucoma

Sapienza

Kim

Rodríguez

et al. 2018

Veterinary Ophthalmology

View full text Add to dashboard Cite

Objective The purpose of this study was to report the preliminary results of a novel micropulse transscleral diode laser cyclophotocoagulation (MP‐TSCP) as primary therapy for glaucomatous dogs. Animal Studied Client owned dogs undergoing MP‐TSCP therapy at a veterinary referral center. Procedure Retrospective study of dogs with glaucoma that were treated with MP‐TSCP with a minimum of 1 month (range: 1‐18 months) of follow‐up. Reported outcomes were intraocular pressure (IOP), treatment parameters, reduction in medications, complications, and incidence of repeat therapy. Results Thirty dogs (35 eyes) were evaluated. The mean age was 9.0 years. Mean preoperative IOP was 34.5 mm Hg. Mean postoperative IOP at 1 month (35/35 eyes) was 22 mm Hg, 2 months (26/35 eyes) was 20.5 mm Hg, 4 months (20/35 eyes) was 19 mm Hg, 6 months (10/35 eyes) was 19 mm Hg, 12 months (8/35 eyes) was 21 mm Hg. First treatment success rate was 19/35 eyes (54.3%). Repeat laser was performed in 11 eyes with 4/11 eyes responding favorably for a total IOP control of 23/35 eyes (65.7%). Mean energy levels employed were 137.5 seconds and 2351 mW at 31.3% duty cycle. Reduction in medications was from a mean of 3.6 medications preoperatively to 3.1 medications postoperatively. Complications included corneal ulcers 5/35 eyes (14.3%), uncontrolled IOP in 12/35 eyes (34.3%) and repeat treatment in 11/35 eyes (31.4%). Conclusions MP‐TSCP was successful in controlling IOP in most patients as well as to reduce postoperative medications with minimal resultant intraocular inflammation and complications. The micropulse procedure also can be repeated. Future investigations to study effective treatment parameters are warranted in a larger series of patients over a longer period of evaluation.

show abstract

Section: Discussionmentioning

confidence: 91%

Section: Resultsmentioning

confidence: 99%

Preliminary findings in 30 dogs treated with micropulse transscleral cyclophotocoagulation for refractory glaucoma

Sapienza

Kim

Rodríguez

et al. 2018

Veterinary Ophthalmology

View full text Add to dashboard Cite

show abstract

“…Energy levels may also have to be adjusted when treating blue-eyed dogs, in which higher energy levels may be required because there is less uveal pigment. 24 Although a significant difference in the amount and distribution of pigment in the CPs of blueeyed and brown-eyed dogs has not been found, 33 the amount of pigment in the CB changes with different intensities of iris color, and increases with age in all breeds. 34 At the conclusion of the procedure, an immediate increase in IOP is frequently seen.…”

Section: Surgical Treatment Of Canine Glaucomamentioning

confidence: 97%

Surgical Treatment of Canine Glaucoma

Bras¹,

Maggio²

2015

Veterinary Clinics of North America: Small Animal Practice

View full text Add to dashboard Cite

“…Even though ECP has been used by veterinary ophthalmologists for over 10 years, peer‐reviewed publications of large case series are lacking and considered of high priority by our group. The use of laser cyclophotocoagulation may be potentially less effective in color‐diluted dogs with blue irises and no pigment in the ciliary musculature possibly resulting in less absorption of laser energy for photocoagulation …”

Section: Novel Surgical Therapies To Control Iopmentioning

confidence: 99%

“…The use of laser cyclophotocoagulation may be potentially less effective in color-diluted dogs with blue irises and no pigment in the ciliary musculature possibly resulting in less absorption of laser energy for photocoagulation. 81 The introduction of microinvasive or minimally invasive glaucoma surgeries (MIGS) in the surgical management of open-angle glaucoma in humans represents an innovative development. The impact of the various MIGS remains to be determined with long-term outcomes of effective IOP reduction and complications, and with appropriate comparative effectiveness trials and meta-analyses.…”

Section: Therapies To Control Iopmentioning

confidence: 99%

The future of canine glaucoma therapy

Komàromy

Bras²,

Esson

et al. 2019

Veterinary Ophthalmology

View full text Add to dashboard Cite

Canine glaucoma is a group of disorders that are generally associated with increased intraocular pressure (IOP) resulting in a characteristic optic neuropathy. Glaucoma is a leading cause of irreversible vision loss in dogs and may be either primary or secondary. Despite the growing spectrum of medical and surgical therapies, there is no cure, and many affected dogs go blind. Often eyes are enucleated because of painfully high, uncontrollable IOP. While progressive vision loss due to primary glaucoma is considered preventable in some humans, this is mostly not true for dogs. There is an urgent need for more effective, affordable treatment options. Because newly developed glaucoma medications are emerging at a very slow rate and may not be effective in dogs, work toward improving surgical options may be the most rewarding approach in the near term. This Viewpoint Article summarizes the discussions and recommended research strategies of both a Think Tank and a Consortium focused on the development of more effective therapies for canine glaucoma; both were organized and funded by the American College of Veterinary Ophthalmologists Vision for Animals Foundation (ACVO‐VAF). The recommendations consist of (a) better understanding of disease mechanisms, (b) early glaucoma diagnosis and disease staging, (c) optimization of IOP‐lowering medical treatment, (d) new surgical therapies to control IOP, and (e) novel treatment strategies, such as gene and stem cell therapies, neuroprotection, and neuroregeneration. In order to address these needs, increases in research funding specifically focused on canine glaucoma are necessary.

show abstract

Distribution and amount of pigment within the ciliary body and iris of dogs with blue and brown irides

Abstract: Compared to eyes with brown irides, eyes with blue irides lack pigment around the CB musculature, but contain comparable amounts of pigment in the CP.

Cited by 5 publications

References 13 publications

Preliminary findings in 30 dogs treated with micropulse transscleral cyclophotocoagulation for refractory glaucoma

Preliminary findings in 30 dogs treated with micropulse transscleral cyclophotocoagulation for refractory glaucoma

Surgical Treatment of Canine Glaucoma

The future of canine glaucoma therapy

Contact Info

Product

Resources

About